Alzheimer's Disease: Pathophysiology, Hypotheses and Treatment Strategies

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder. One new case of AD is expected to be developed every 33 seconds. So, about million new cases will be developed per year and the total estimated prevalence is expected to reach 13.8 million by 2050 [1]. AD is characterized by a group of symptoms classified as cognitive and non-cognitive dysfunctions. The cognitive dysfunction includes memory loss, executive dysfunction and language difficulties while noncognitive dysfunction includes behavioral disturbances and psychiatric symptoms as hallucinations, delusion, agitation as well as depression [2]. In the late stage of the disease, cognitive performance of AD patients greatly declines to such an extent that they need complete support for all their daily activities [3, 4].

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.4172/2469-6676.100049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Potential Effect of Caffeine and Nicotine Co-administration againstAluminum-induced Alzheimer's disease in Rats

  2016cited by this paper
• Comparative Study on the Influence of Epigallocatechin-3-gallat e and/or Coenzyme Q10 against Alzheimer's disease Induced by Aluminiumin Normally-Fed and Protein Malnourished Rats

  2016cited by this paper
• The Potential Effect of Epigallocatechin-3-Gallate alone or in Combination with Vitamin E and Selenium on Alzheimer’s Disease Induced by Aluminum in Rats

  2016cited by this paper
• Classification of behaviors in dementia based in impairment in theories based upon information processing pathways

  2015cited by this paper
• Classification of behaviors in dementias based on principles of compliance and aggression

  2015cited by this paper
• Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities.

  2013cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• The history of the cholinergic hypothesis.

  2011cited by this paper
• Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer's Disease

  2011cited by this paper
• Cellular basis of Alzheimer’s disease

  2010cited by this paper
• Somatostatin and Alzheimer's disease.

  2008cited by this paper
• Donepezil: an update

  2007cited by this paper
• The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism

  2007cited by this paper
• Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses

  2007cited by this paper
• Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms

  2006cited by this paper
• Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation

  2005cited by this paper
• Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

  2003cited by this paper
• Apolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses

  2000cited by this paper
• Translating cell biology into therapeutic advances in Alzheimer's disease

  1999cited by this paper
• Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.

  1999cited by this paper
• Increase in the Number, G Protein Coupling, and Efficiency of Facilitatory Adenosine A2A Receptors in the Limbic Cortex, but not Striatum, of Aged Rats

  1999cited by this paper
• Corticotropin‐Releasing Factor (CRF), CRF‐Binding Protein (CRF‐BP), and CRF/CRF‐BP Complex in Alzheimer's Disease and Control Postmortem Human Brain

  1997cited by this paper
• Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E.

  1995cited by this paper
• Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content

  1990cited by this paper
• CSF somatostatin in Alzheimer's disease.

  1984cited by this paper

• Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis

  2023cites this paper
• A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimer's Disease.

  2021cites this paper
• Role of IL-6/STAT3 pathway in mediating the protective effect of agomelatine against methotrexate-induced lung/intestinal tissues damage in rats

  2021cites this paper
• Antioxidant , In-Vitro Anti-Inflammatory and Anti-Alzheimer Activities of Methanolic Fraction of Salvia Miltiorrhiza Flower

  2019cites this paper
• Current viral-mediated gene transfer research for treatment of Alzheimer’s disease

  2018cites this paper